CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


SARS-CoV-2 PCRWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug2191 Sample collection Wiki 0.71

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Norwegian SARS-CoV-2 Study - Virological, Clinical and Immunological Characterisation of Inpatients During the COVID-19 Outbreak: A Prospective Cohort Study

Oslo University Hospital has initiated an observational study on hospitalised patients with confirmed COVID-19, the infection caused by Severe Acute Respiratory Syndrome Coronavirus type 2 (SARS-CoV-2).

NCT04381819 SARS Virus Severe Acute Respiratory Syndrome Diagnostic Test: SARS-CoV-2 PCR
MeSH:Severe A Severe Acute Respiratory Syndrome Coronavirus Infections

Primary Outcomes

Description: Fatal outcome from COVID-19

Measure: Death

Time: From date of randomization until the date of death from any cause assessed up to 3 months.

Description: Resolved infection

Measure: Recovery from COVID-19

Time: From date of randomization until the date of recovery from COVID-19 symptoms assessed up to 3 months.

Description: Percentage of patients requiring intensive care admission or ventilation

Measure: Progression to ICU care or ventilation

Time: 30 days

Secondary Outcomes

Description: The change in(clearance of) viral RNA measured by polymerase chain reaction assay (PCR) test at days 1, 3, 8,14 and 90 days

Measure: Clearance of SARS-CoV-2 from respiratory specimen

Time: The number of calendar days from date of PCR positive test (counted as 1 day) in respiratory specimen until date of such test first become negative in the respiratory specimen assessed up to 3 months

Description: Cell-mediated and humoral immunity

Measure: Immune response to COVID-19

Time: From date of randomization until the date of clinical follow-up assessed up to 3 months.


No related HPO nodes (Using clinical trials)